Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand

BACKGROUND: Many patients develop tumour recurrence within a few years after undergoing surgical resection of gastrointestinal stromal tumours (GIST). Adjuvant imatinib treatment is recommended for patients with high risk of GIST recurrence as it can improve recurrence-free survival and overall surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Bussabawalai, Thanaporn, Thiboonboon, Kittiphong, Teerawattananon, Yot
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323771/
https://www.ncbi.nlm.nih.gov/pubmed/30636935
http://dx.doi.org/10.1186/s12962-018-0169-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323771/
https://www.ncbi.nlm.nih.gov/pubmed/30636935
http://dx.doi.org/10.1186/s12962-018-0169-9

Ejemplares similares